hematologic neoplasms

..addition, dramatically increased expression of components of the Wnt/b-catenin pathway is found in many hematological malignancies. We have shown that Wnt signaling induces an interaction between GCKR and GSK3#], a key kinase in the ..

..provided by applicant): Allogeneic stem cell transplantation (alloSCT) is a life-saving therapy for hematologic malignancies and inherited disorders such as sickle cell anemia and thalassemia...

..Pilot Study of Non-myeloablative, HLA-matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies," PI: Alan S. Wayne, M.D.c...

..provided by applicant): Allogeneic stem cell transplantation (alloSCT) is a life-saving therapy for hematologic malignancies and inherited disorders such as sickle cell anemia and thalassemia...

..Murine leukemia viruses (MuLVs) have been implicated in the spontaneous development of hematopoietic neoplasms involving both T and B cells in mice...

..Allogeneic hematopoietic stem cell transplantation (allo-HCT) is an established therapy for several hematologic malignancies. There exists considerable evidence that adoptive immunotherapy in the form of a donor T-cell mediated ..

..by applicant): Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment of hematological malignancies and related disorders with more than 40,000 transplants conducted each year...

..by applicant): Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment of hematological malignancies and related disorders with more than 40,000 transplants conducted each year...

..GVHD, disease relapse, and survival among individuals who have undergone allogeneic BMT for treatment of hematologic malignancies. Using existing treatment related data from the University of Minnesota BMT database and stored ..

..of non-myeloablative allogeneic hematopoietic stem cell transplantation (NST) for the treatment of non-hematologic malignancies. We have selected Human Papilloma Virus (HPV)-associated cervical cancer as a model because it ..

..stem cell transplantation (HSCT) is frequently used in clinical practice to cure or improve survival of hematological malignancies. Phase III randomized trials have shown that this approach is more effective than non-intensive therapy ..

..significant clinical use, is performing mismatched stem cell transplants for high-risk and refractory hematological malignancies using related donors...

..Applicant's Abstract) Allogeneic hematopoietic stem cell transplantation (HSCT) is curative therapy for hematologic malignancies, aplastic anemia and a variety of genetic conditions; however, significant treatment-related morbidity ..

..Applicant's Description Verbatim): Allogeneic bone marrow transplantation is a curative therapy for hematologic malignancies, marrow failure states, and selected inherited metabolic diseases...

..Hematopoietic stem cell transplantation is a potentially curative therapy for patients with advanced hematological malignancies. Recently, mobilized peripheral blood HPC instead of bone marrow-derived HPC have been used because of ..

..Hematopoietic stem cell transplantation is a potentially curative therapy for patients with advanced hematological malignancies. Recently, mobilized peripheral blood HPC instead of bone marrow-derived HPC have been used because of ..

..transplantation (alloHSCT) is currently the only curative treatment available for patients with certain hematologic malignancies including B cell chronic lymphocytic leukemia (B-CLL)...

DESCRIPTION (provided by applicant): Allogeneic transplantation is an effective therapy for hematologic malignancies and exerts its therapeutic effects through grafts vs leukemia effects...

..Therapy of patients with chemotherapy resistant hematologic malignancies has been remarkably effective with Fv-toxins recombinant immunotoxins) targeting CD25 or CD22 in hairy ..

..peripheral blood hematopoietic stem cell (PBSC) transplantation is frequently used for treating various hematologic malignancies. To facilitate this process, autologous PBSC are typically collected, cryopreserved and stored for some ..

..When using allogeneic HCT as a therapy for hematological malignancies, however, the graft- versus-tumor (GVT) effect is in large part associated with graft-versus-host ..

..When using allogeneic HCT as a therapy for hematological malignancies, however, the graft- versus-tumor (GVT) effect is in large part associated with graft-versus-host ..

..When using allogeneic HCT as a therapy for hematological malignancies, however, the graft- versus-tumor (GVT) effect is in large part associated with graft-versus-host ..

..Hematopoietic cell transplantation (HCT) is an effective therapy for patients with a broad range of hematologic malignancies. The benefits of HCT are in large part derived from the immunological recognition of malignant cells ..

The goal of hematopoietic cell transplantation (HCT) for hematologic malignancies is sustained eradication of disease...

..laboratory investigation related to applied research in experimental therapeutics of solid tumor or hematologic malignancies; 2] The second group includes MD or MD/PhD faculty who pursue patient-related research in clinically ..

..to promising outcomes and safety of non-myeloablative HSCT, this procedure is increasingly used to treat hematologic malignancies and has enormous potential for treating a variety of diseases...

..peripheral blood hematopoietic stem cell (PBSC) transplantation is frequently used for treating various hematologic malignancies. To facilitate this process, autologous PBSC are typically collected, cryopreserved and stored for some ..

..with significant morbidity and economic cost, limiting its use to the treatment of life-threatening hematopoietic malignancies. In contrast, mouse embryonic stem cells (ESC) are poorly immunogenic because of their low expression of ..

..or marrow transplantation (BMT) is a highly effective and potentially curative treatment for a number of hematopoietic malignancies due to the associated Graft versus Leukemia (GVL) effect...

..T-cell depleted non-myeloablative allogeneic stem cell transplantation in adult patients with high risk hematologic malignancies. The incidence and severity of graft vs host disease will be a primary endpoint...

..of insulin resistance and the MS in adolescent and young adult survivors after HCT for treatment of hematologic malignancies in childhood, and this application is the result of the successful progression of Dr...

Allogeneic stem cell transplantation (alloSCT) is life-saving therapy for hematologic malignancies and inherited disorders such as sickle cell anemia and thalassemia...

..Similar approach can be applied to other hematopoietic malignancies such as leukemias and lymphomas...

..of insulin resistance and the MS in adolescent and young adult survivors after HCT for treatment of hematologic malignancies in childhood, and this application is the result of the successful progression of Dr...

..rolling potential of stem cells can be exploited to influence capture, adhesion, and apoptosis in hematologic malignancy states...

DESCRIPTION (provided by applicant): Hematological malignancies display a spectrum of phenotypes. At one end is acute leukemia, characterized by proliferation of a population of cells blocked in their differentiation...

DESCRIPTION (provided by applicant): Hematological malignancies display a spectrum of phenotypes. At one end is acute leukemia, characterized by proliferation of a population of cells blocked in their differentiation...

DESCRIPTION (provided by applicant): Hematological malignancies display a spectrum of phenotypes. At one end is acute leukemia, characterized by proliferation of a population of cells blocked in their differentiation...

..HCT) and the translation of concepts to the clinic to improve the outcomes for patients with serious hematological malignancies. The overarching hypothesis of this proposal is that cellular components are critical to transplantation ..

..HSCs) from human ES cells may be used for hematopoietic cell transplantation therapies for patients with hematologic malignancies such as leukemia or myeloma...

..PUBLIC HEALTH RELEVANCE: Most of patients with acute myeloid leukemia (AML), a type of hematopoietic malignancies, have dismal outcome with current chemotherapy treatment, especially if older than 60 years, and ..

..Dose intense radiation and chemotherapy as applied in the treatment of hematologic malignancies commonly result in prolonged cytopenias as a function of bone marrow (BM) suppression...

..provided by applicant): Doxorubicin (Dox) is an anthracycline antineoplastic drug commonly used against hematologic malignancies and solid tumors for over 30 years...

..HCT) and the translation of concepts to the clinic to improve the outcomes for patients with serious hematological malignancies. The overarching hypothesis of this proposal is that cellular components are critical to transplantation ..

..institution of the DNMT inhibitor 5AC in combination with HDAC inhibitors phenylbutyrate or MS- 275 in hematologic malignancies have resulted in remarkable clinical activity associated with reversal of epigenetic changes in key tumor ..

..For patients with refractory hematologic malignancies, BMT, particularly from HLA-mismatched donors, has rarely been successful...

..institution of the DNMT inhibitor 5AC in combination with HDAC inhibitors phenylbutyrate or MS- 275 in hematologic malignancies have resulted in remarkable clinical activity associated with reversal of epigenetic changes in key tumor ..

..serves as a centralized resource to the investigators of the Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Program Project Grant (PPG), providing biostatistical expertise, clinical research management and ..

..DESIGN AND METHODS: We analyzed 1180 consecutive patients with leukemia (n=979) or other hematologic malignancies (n=201) undergoing HSCT in 4 time periods: before 1990, 1991-1995, 1996-2000, and 2001-2002...

..myelogenous leukemia (CML) in chronic phase was associated with low risk for early IA compared with other hematologic malignancies, aplastic anemia, and myelodysplastic syndrome...

..allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning (RIC HSCT) for hematological malignancies and were reported to the Société Française de Greffe de Moelle et de Thérapie Cellulaire registry ..

..A multivariate analysis demonstrated a significantly worse survival rate after transplantation for female recipients, advanced disease and acute leukemia before transplantation...

..Our results indicate that non-T-cell-depleted HLA-haploidentical SCT may be feasible, with appropriate GVHD prophylaxis, for young recipients who lack immediate access to a conventional stem cell source...

..RESULTS: Forty-nine patients with hematologic malignancies or marrow failure and no other available donors were enrolled...

..The role of recombinant FVIIa as a hemostatic agent for the treatment of HSCT-associated hemorrhage will be briefly explored...

..No relation was found between TNF polymorphic features and aGvHD incidence by either uni- or multivariable analyses...

..CONCLUSION: The incidence and severity of ARF, as well as nonrelapse mortality, occurring after nonmyeloablative HCT is significantly lower compared with myeloablative HCT...

..Male predominance was detected in LHC after HSCT, as has been previously shown in children with AdV-induced acute HC. The detection of AdV DNA in serum did not predict a poor outcome...

..78). These results show that MC is an important predictive factor, especially in patients over 30 years of age...

....

..In summary, a nonmyeloablative regimen incorporating in vivo CAMPATH-1H is effective in promoting durable engraftment in most patients and in reducing the risk of severe GVHD following matched unrelated donor transplantation...

..This novel reduced intensity preparative regimen was well tolerated and associated with a low incidence of transplant-related mortality and serious acute and cGVHD...

..Our results also showed that high-dose Bu (16 mg/kg) for the conditioning and FK506 for the prophylaxis of GVHD might contribute more significantly to TMA onset after HSCT than other agents...

..In conclusion, DLI is a potential treatment strategy, with acceptable toxicity, for patients with persistent, relapsed, or progressive disease after nonmyeloablative hematopoietic cell transplantation...

..The main problem is a high risk to develop graft versus host reaction, especially a chronic form...

A second allogeneic hematopoietic stem cell transplant (HSCT) for relapsed hematologic malignancies is an option in select patients after an initial allograft has failed...

..4% for PMC (P < 0.0001 and P < 0.0001). Multivariate analysis only showed a significant impact of chimaerism status on OS, as well as acute and chronic graft-versus-host disease on EFS, with a trend for conditioning regimen...

..krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen...

..It is particularly suitable for the treatment of older patients at high risk with regard to their disease...

..3% +/- 8.3% versus 51.8% +/- 10.5%; P = .60) are without detectable difference, PBPC and BM appear both as a valid stem cell source for HLA-matched unrelated donor transplantation in children with hematologic malignancies.

..08). For patients receiving RIST without complete remission, relapse and infection were the main causes of death. Our data suggest that patients without complete remission should receive CST to the degree possible...

....

....

..INTERPRETATION AND CONCLUSIONS: We have shown that immunosuppressed patients can exhibit anti-FCS antibodies, but no alloantibodies, that may bind to MSC. These antibodies seem clinically insignificant...

..01). In multivariate analysis adjusted for diagnosis, busulphan-treated patients showed both a better survival (P=0.04) and less probability of relapse (0.03) compared to TBI-treated patients...

..combination prior to allogeneic hematopoietic stem cell transplant in patients with various hematological malignancies not eligible for conventional regimens because of previous intensive treatment, older age, and ..

..Chimerism in granulocytes and PBMC subsets did show great intra-individual differences in the subsets and these data correlated well with RCP and CYT data with the exception of the NK cells...

Nineteen adult patients with poor-risk hematologic malignancy received T cell-depleted (TCD) hematopoietic progenitor cell (HPC) transplant from partially mismatched related donors (PMRD)...

..Membranous nephropathy resulting in NS is a previously unrecognised and clinically significant complication of non-myeloablative HCT...

..transplantation (HSCT) from a histocompatibility leukocyte antigen identical sibling donor for different hematological malignancies. The dose of CD34+, CD3+, CD4+, CD8+, and CD19+ lymphocytes, natural killer (NK) cells, natural killer T ..

..patients undergoing matched unrelated donor allogeneic hematopoetic stem cell transplantation (HSCT) for hematologic malignancies. A dose of 60 mg/kg body weight has previously been recommended for ATG-F...

..CONCLUSIONS: This study provides an important new approach to the improvement of immune reconstitution in patients undergoing hemopoietic stem cell transplantation and may have generic applications in many T cell-based disorders...

..Although a significant improvement in the prevention of GVHD was not suggested, compared with CSP and MTX, MMF in combination with CSP could be considered in cases in which MTX is contraindicated...

..CONCLUSION: We developed a new method to use bone marrow from haploidentical family donors without ex vivo T cell depletion, in combination with G-PBSCs, as a source of stem cells even in cases of HLA mismatched transplantation...

..6 (95% CI 0.2-1.3) P=0.16) and with URD RR 0.4 (0.2-1.0) P=0.04). Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens.

....

..026). Collectively, these results provide a framework for refining nonmyeloablative conditioning, to improve outcome with an acceptable risk of GVHD...

..05) than the recipients of myeloablative conditioning. In contrast, the recipients of nonmyeloablative conditioning had a delayed B cell recovery when compared to the patients who received myeloablative conditioning (P=0.04)...

..Thus, larger randomised studies are required before CDV can be recommended as a primary pre-emptive therapy for post-transplant CMV infections...

....

..In conclusion, this regimen is promising in high risk patients lacking a suitable donor, and a prospective phase I/II study is ongoing...

..CONCLUSION: Outcome following T cell-depleted PBPCT critically depends on the number of CD3(+) T cells, whereby high T-cell numbers may blunt a favorable effect of higher CD34(+) cell numbers...

..Further studies are required to confirm these findings...

..We conclude that basiliximab is efficient and feasible for steroid-refractory aGVHD and merits further evaluation...

..disease, infections, and the kinetics of immune reconstitution in 28 patients with very poor-risk hematologic malignancies who received lymphocyte-depleted, CD34(+) cell-enriched hematopoietic progenitor cell grafts from ..

..A reduction in conditioning intensity is associated with poor survival for patients with advanced-stage disease, highlighting the importance of the conditioning regimen for tumor control...

..RICT from a one-locus-mismatched donor may represent an effective alternative approach in patients with high-risk malignancies who lack HLA-matched related donors...

..Overall survival is 5/10 patients (50%) with a median follow-up of 435 (range, 229-814) days. CONCLUSION: This regimen is promising in high-risk patients lacking a suitable donor, and a prospective phase I/II study is ongoing...

..The low incidence of early GVHD enabled the subsequent administration of DLI to improve further clinical responses in this poor-risk group of lymphoma and myeloma patients...

..5 years) with hematological malignancies treated with 18 allo-SCT procedures, mostly nonmyeloablative...